E 6080

E 6080 is an orally active and selective 5-lipoxygenase (5-LOX) inhibitor with an IC50 of 0.2 μM in rat basophilic leukemia cell. E 6080 shows potent inhibitory effects on the release of leukotrienes. E 6080 inhibits the bronchospasm induced by antigen (ovalbumin) inhalation in sensitized conscious guinea pigs. E 6080 can be used for the study of asthma[1][2][3].

120164-49-0

12352005

Leukotriene Receptor; Lipoxygenase

GPCR/G Protein; Metabolic Enzyme/Protease

Inflammation/Immunology

O=S(N)(C1=CC=C(CNC2=NC3=C(C)C(C)=C(O)C(C)=C3S2)C=C1)=O.Cl

C17H20ClN3O3S2

413.94

[1]Tsunoda H, et al. Effect of a novel 5-lipoxygenase inhibitor, E6080 on bronchospasm, airway cellular infiltration and leukotriene production in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 1991 Jan;42 (1) :51-6. |[2]Katayama S, et al. Inhibition of IgE-mediated leukotriene generation and bronchoconstriction in primates with a new 5-lipoxygenase inhibitor, E6080. Int Arch Allergy Immunol. 1993;100 (2) :178-84. |[3]Sakuma Y, et al. Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro. Int Arch Allergy Immunol. 1992;97 (4) :267-73.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-180363/

Reference compound1

No Development Reported

5-LOX; LTB4; LTC4/CysLT2